3FYJ

Crystal structure of an optimzied benzothiophene inhibitor bound to MAPKAP Kinase-2 (MK-2)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.80 Å
  • R-Value Free: 0.388 
  • R-Value Work: 0.328 
  • R-Value Observed: 0.331 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency.

Anderson, D.R.Meyers, M.J.Kurumbail, R.G.Caspers, N.Poda, G.I.Long, S.A.Pierce, B.S.Mahoney, M.W.Mourey, R.J.Parikh, M.D.

(2009) Bioorg Med Chem Lett 19: 4882-4884

  • DOI: https://doi.org/10.1016/j.bmcl.2009.02.017
  • Primary Citation of Related Structures:  
    3FYJ, 3FYK, 3FZ1

  • PubMed Abstract: 

    Optimization of kinase selectivity for a set of benzothiophene MK2 inhibitors provided analogs with potencies of less than 500 nM in a cell based assay. The selectivity of the inhibitors can be rationalized by examination of X-ray crystal structures of inhibitors bound to MK2.


  • Organizational Affiliation

    Pfizer Global Research and Development, St Louis Laboratories, Chesterfield, MO 63017, USA. david.r.anderson@pfizer.com


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
MAP kinase-activated protein kinase 2A [auth X]327Homo sapiensMutation(s): 0 
Gene Names: MAPKAP-2MAPKAPK2
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for P49137 (Homo sapiens)
Explore P49137 
Go to UniProtKB:  P49137
PHAROS:  P49137
GTEx:  ENSG00000162889 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP49137
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
B97
Query on B97

Download Ideal Coordinates CCD File 
B [auth X](10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one
C21 H18 N4 O S
CMWRPDHVGMHLSZ-GFCCVEGCSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
B97 BindingDB:  3FYJ Ki: 5 (nM) from 1 assay(s)
IC50: min: 5, max: 201 (nM) from 2 assay(s)
PDBBind:  3FYJ IC50: 5 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.80 Å
  • R-Value Free: 0.388 
  • R-Value Work: 0.328 
  • R-Value Observed: 0.331 
  • Space Group: F 41 3 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 255.551α = 90
b = 255.551β = 90
c = 255.551γ = 90
Software Package:
Software NamePurpose
DENZOdata reduction
SCALEPACKdata scaling
REFMACrefinement
PDB_EXTRACTdata extraction
ADSCdata collection
HKL-2000data reduction
AMoREphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2009-04-07
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2017-11-01
    Changes: Refinement description
  • Version 1.3: 2023-09-06
    Changes: Data collection, Database references, Derived calculations, Refinement description